Oral Genome, a leader in saliva-based oral health testing, has been honored with the 2025 Cellerant Best of Class Hygiene Award, recognizing the company’s innovative contribution to preventive oral care.
Presented annually by Cellerant Consulting Group, the award celebrates products that are revolutionizing dental hygiene. This year’s panel of dental hygiene experts selected 21 products that demonstrate innovation, clinical impact, and patient-centered design. Oral Genome’s Oral Health Saliva Test delivers rapid, chairside insights into oral and systemic health markers in just 15 minutes—empowering dental professionals to bridge preventive care, early detection, and whole-body wellness.
“This award recognizes the power of real-time saliva testing in modern preventive care. With Oral Genome, clinicians can identify inflammation and risk in minutes and help patients take action immediately. It’s exciting to see this shift toward data- driven prevention acknowledged at the national level.” says Dr. Tina Saw, CEO and Founder of Oral Genome
The Mechanics of a More Connected Healthcare Ecosystem [Video]
Arbiter’s Anjali Jameson on hospital and payer alignment.
The Cellerant award highlights Oral Genome’s mission to make precision, preventive oral health accessible in every dental office and community across the nation.
To learn more, visit Oral Genome’s website.
Beacon Biosignals, a neurotechnology company supporting AI-driven diagnostics and precision medicines for the brain, has raised an $86 million Series B round to build the world’s largest neurodiagnostic dataset and advance the clinical application of AI-driven biomarkers for brain health, according to a press release. A syndicate of healthcare and technology investors led the round, including Innoviva, Google Ventures, Nexus NeuroTech Ventures, S32, Catalio Capital Management, and Takeda. Previous investors also took part, including General Catalyst, Logos Capital, Casdin Capital, and Indicator Ventures.
The New Blueprint: How Clever Care Health Plan is Scaling Its Member Experience [Video]
MedCity News was at the Vive conference and spoke with executives who shared their insights for the healthcare industry.
Beacon’s FDA-cleared Waveband device measures the brain’s electrical activity during sleep and wake, bringing gold-standard neurophysiology out of the lab and into patients’ homes, the release said.
“Our mission is to make brain function measurable and actionable at scale,” said Dr. Jacob Donoghue, CEO and co-founder of Beacon Biosignals. “By training AI on millions of hours of real-world brain data, we’re beginning to map the signals of health and disease in ways that can accelerate drug development and ultimately improve how patients are diagnosed and treated.”
To learn more, click here.
Modulight Biotherapeutics, developer of novel optogenetic platform for the treatment of neurological disorders, has closed a $12.2 million seed funding round. Jibe Ventures and LocalGlobe led the round, with participation from Nexus Neurotech Ventures, RedSeed VC, Secret Chord Ventures, Fresh Fund, Saras Capital, SilverArc Capital and Sha’ar Mivnim. The funding will enable the business to accelerate the development of its optogenetic technology platform and advance its therapeutic product pipeline towards the clinic, according to a press release.
“This funding marks a significant milestone for Modulight Biotherapeutics as we advance our mission to develop light-based therapeutics for the treatments of severe neurological diseases,” said Dr. Yotam Eldar, Modulight Biotherapeutics CEO. “The financial round will allow us to enhance the preclinical development of our optogenetic switch for the treatment of trigeminal pain and initiate IND-enabling studies, manufacturing and discussions with the FDA.”
To learn more, click here.
No Barrier has raised a $2.7 million seed round to support the development of its AI-powered medical translation tool. It seeks to redefine language access in healthcare. A-Squared Ventures, Esplanade Ventures, Rock Health Capital and Fusion led the round, according to a press release.
No Barrier’s real time language interpretation technology integrates into existing clinician workflows, according to the company, improving providers’ and health systems’ limited-English-proficiency services with zero-wait access. Unlike generic AI translators, No Barrier’s solution is purpose-built for healthcare — seamlessly integrating into clinical systems with HIPAA-grade security and EHR workflow support.
This new funding accelerates expansion across all points of care, from appointment check-in to treatment plans, ensuring language access throughout every patient journey.
To learn more, click here.
LabCentral has launched LabCentral First, a new program to provide high-potential life sciences companies with access to LabCentral’s lab facilities free of charge for the first six months. Eligible startups must be led by first-time founders/CSOs – either new to entrepreneurship, new to Massachusetts, or targeting underfunded novel indications – pursuing high-impact science, according to a press release.
“As an economic development non-profit, LabCentral has always been committed to supporting early-stage entrepreneurs at the forefront of life sciences innovation in Massachusetts,” said Maggie O’Toole, LabCentral President and CEO. “In this particularly challenging funding environment, we are seeing first-time entrepreneurs struggle to get the seed funding that historically allowed them to move in with their initial bench, gather critical early-stage data, and advance their science. LabCentral First provides that crucial ‘foot-in-the-door’ moment.”
To learn more, click here.
Photo: Richard Drury, Getty Images
This is a paid member feature of MedCitizens. Please submit here and join!